1189983-52-5
Chemical Structure
Dipyridamole-d20
- CAS No.: 1189983-52-5
- Formula:C24H20D20N8O4
- Molecular Weight:524.75
IUPAC Name: 2,2',2'',2'''-((4,8-bis(piperidin-1-yl-d10)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetrakis(ethan-1-ol)
InChIKey: IZEKFCXSFNUWAM-KHKAULECSA-N
SMILES: N(CCO)(CCO)C1=NC2=C(C(=N1)N3C(C(C(C(C3([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])N=C(N(CCO)CCO)N=C2N4C(C(C(C(C4([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H]
Biological Activity: Dipyridamole-d20 is the deuterium labeled Dipyridamole. Dipyridamole is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dipyridamole-d20 | Dipyridamole-d20 is the deuterium labeled Dipyridamole. Dipyridamole is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dipyridamole (Standard) | ≥98% | Dipyridamole (Standard) is the analytical standard of Dipyridamole. This product is intended for research and analytical applications. Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dipyridamole-d16 | Dipyridamole-d16 is the deuterium labeled Dipyridamole. Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dipyridamole | 99.93% | Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Klabunde, R.E., Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol, 1983. 93(1-2): p. 21-6. [Content Brief]
- [3]. Best, L.C., et al., Mode of action of dipyridamole on human platelets. Thromb Res, 1979. 16(3-4): p. 367-79. [Content Brief]
